Skip to main content

Advertisement

Log in

The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery

  • Original article
  • Published:
Journal of Hepato-Biliary-Pancreatic Surgery

Abstract

Background

Pancreatic carcinoma causes more than 20,000 deaths every year in Japan. The role of (neo-) adjuvant chemotherapy for pancreatic carcinoma is still controversial.

Methods

At the 34th Annual Meeting of the Japanese Society of Pancreatic Surgery in 2007, questionnaires were distributed regarding the use of (neo-) adjuvant chemo(radio)therapy for pancreatic carcinoma between 2001 and 2005.

Results

Sixty of the 146 member institutions responded to the questionnaires. There were a total of 1,846 cases of resected pancreatic carcinoma between 2001 and 2005. The study population had a greater proportion of males, and a mean age of 65.3 years (range 34–90 years). The lesion was located in the head of the pancreas in 1,204 cases (71.7%), in the body in 353 cases (21.0%), and in the tail in 111 cases (6.6%). Overall survival rates were 67.3% at 1 year, 36.0% at 2 years, and 23.9% at 3 years, respectively. Adjuvant chemotherapy (usually involving gemcitabine) was used in 66.0% of cases. The use of adjuvant chemotherapy was found to improve the overall survival rate. Interestingly, adjuvant chemotherapy only improved survival in late-stage (UICC stages IIB, III, and IV) but not early stage (IA, IB, and IIA) patients. Survival was treatment duration-dependent, with patients who received more than 12 months of therapy having a 3-year survival rate of 51.2%.

Conclusion

This high volume retrospective data indicated the promising effect of gemcitabine-based adjuvant chemotherapy and the rational duration of adjuvant chemotherapy should be determined in the future prospective studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. The website of Japanese Ministry of Health, Labour and Welfare [http://www.mhlw.go.jp/toukei/].

  2. Fortner JG. Regional pancreatectomy for carcinoma of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg. 1984;199:418–25.

    Article  PubMed  CAS  Google Scholar 

  3. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg. 1998;228:508–17.

    Article  PubMed  CAS  Google Scholar 

  4. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355–66.

    Article  PubMed  Google Scholar 

  5. Nguyen TC, Sohn TA, Cameron JL, Lillemoe KD, Campbell KA, Coleman J, et al. Standard vs radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg. 2003;7:1–9.

    Article  PubMed  Google Scholar 

  6. Burris HAIII, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.

    PubMed  CAS  Google Scholar 

  7. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, et al. 30 Years’ follow up of randomised studies of adjuvant CMF in operable breast cancer cohort study. BMJ. 2005;330:217.

    Article  PubMed  Google Scholar 

  8. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9.

    Article  PubMed  CAS  Google Scholar 

  9. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–13.

    Article  PubMed  CAS  Google Scholar 

  10. Leichman CG. Adjuvant therapy for colon cancer 2005: new options in the twenty-first century. Surg Oncol Clin North Am. 2006;15:159–73.

    Article  Google Scholar 

  11. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

    Article  PubMed  CAS  Google Scholar 

  12. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.

    Article  PubMed  CAS  Google Scholar 

  13. The committee of pancreatic carcinoma registration of Japan Pancreas Society. Summary of 20-years registration of pancreatic carcinoma conducted by JPS. Pancreas [Japanese edition]. 2003;18:97–169.

    Google Scholar 

  14. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.

    PubMed  CAS  Google Scholar 

  15. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006–10.

    Article  Google Scholar 

  16. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225:621–33.

    Article  PubMed  CAS  Google Scholar 

  17. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.

    Article  PubMed  CAS  Google Scholar 

  18. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776–84.

    Article  PubMed  CAS  Google Scholar 

  19. Bakkevold KE, Arnesjø B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater—results of a controlled, prospective, randomised multicentre study. Eur J Cancer. 1993;29A:698–703.

    Article  PubMed  CAS  Google Scholar 

  20. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–85.

    Article  PubMed  CAS  Google Scholar 

  21. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Caner. 2002;95:1685–95.

    Google Scholar 

  22. Kosuge T, Kiuchi T, Mukai K, Kakizoe T, Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP). A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006;36:159–65.

    Article  PubMed  Google Scholar 

  23. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005;68:171–8.

    Article  PubMed  CAS  Google Scholar 

  24. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2006;94:1575–9.

    PubMed  CAS  Google Scholar 

  25. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:615–21.

    Article  PubMed  CAS  Google Scholar 

  26. Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, et al. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology. 2005;69:421–7.

    Article  PubMed  CAS  Google Scholar 

  27. Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, et al. Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2005;92:2134–9.

    Article  PubMed  CAS  Google Scholar 

  28. Shinchi H, Maemura K, Noma H, Mataki Y, Aikou T, Takao S. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer. 2007;96:1353–7.

    PubMed  CAS  Google Scholar 

  29. Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Shirai Y, Nakagawa A, et al. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;67:219–24.

    PubMed  Google Scholar 

  30. Maeda A, Boku N, Fukutomi A, Kondo S, Kinoshita T, Nagino M, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol. 2008;38:227–79.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are especially grateful to the 60 leading Japanese institutions that kindly took part in the survey.

Aichi Medical University, Department of Surgery; Division of Gastroenterol Surgery

Asahikawa Medical College, Department of Gastroenterological Surgery

Chiba Cancer Center, Department of Gastroenterological Surgery

Chiba Rosai Hospital, Department of Surgery

Fujita Health University School of Medicine, Department of Biliary Pancreatic Surgery

Fukui University, Faculty of Medicine, Department of Surgery I

Higashiosaka City General Hospital, Department of Surgery

Hirosaki University School of Medicine, Department of Surgery II

Hiroshima City Hospital, Department of Surgery

Hyogo College of Medicine, Department of Surgery 1

Ikuwakai Memorial Hospital, Department of Surgery

Ise Municipal General Hospital, Department of Surgery

Iwate Medical University School of Medicine, Department of Surgery

Jichi Medical University, Department of Surgery

Jikei University School of Medicine, Department of Surgery

Jikei University School of Medicine, Aoto Hospital, Department of Surgery

Jikei University, Daisan Hospital, Department of Surgery

Jikei University, Kashiwa Hospital, Department of Surgery

Kagawa University, Faculty of Medicine, Department of Gastroenterological Surgery

Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Department of Surgery

Kitakyushu Municipal Medical Center, Department of Surgery

Kitasato University School of Medicine, Department of Surgery

Kobe City Medical Center General Hospital, Department of Surgery

Kobe University Graduate School of Medicine, Department of Hepato-Billiary-Pancreatic Surgery

Kurume University School of Medicine, Department of Surgery

Kyorin University School of Medicine, Department of Surgery

Kyushu University, Faculty of Medicine, Department of Surgery I

Matsusaka City Hospital, Department of Surgery

Meiwa Hospital, Department of Surgery

Miyazaki University School of Medicine, Department of Surgical Oncology and Regulation of Organ Function

Nagasaki University Graduate School of Medicine, Department of Gastroenterological Surgery

Nagoya City University Graduate School of Medical Sciences, Department of Gastroenterological Surgery

Nagoya University Graduate School of Medicine, Department of Gastroenterological Surgery

Nara Medical University, Department of Surgery

National Cancer Center Hospital East, Department of Upper Abdominal Surgery

National Kyushu Cancer Center, Department of Surgery

National Kyushu Medical Center, Department of Surgery

Nihon University School of Medicine, Division of Digestive Surgery

Niigata Prefectural Central Hospital, Department of Surgery

Niigata University School of Medicine, Department of Surgery

Nippon Medical School, Department of Surgery I

Okayama University Graduate School of Medicine, Department of Gastroenterological surgery transplant and Surgical Oncology

Osaka City University Graduate School of Medicine, Department of Hepato-Billiary-Pancreatic Surgery

Osaka City University Graduate School of Medicine, Department of Surgical Oncology

Osaka Rosai Hospital, Department of Surgery

Osaka University Graduate School of Medicine, Department of Gastroentelogical Surgery

Sapporo Medical University, Department of Surgery I

Sapporo-Kosei general Hospital, Department of Surgery

Shinshu University School of Medicine, Department of Surgery

Showa University School of Medicine, Department of Surgery

St. Marianna University School of Medicine, Department of Surgery

St. Marianna University, Yokohama City Seibu Hospital, Department of Surgery

Teikyo University Chiba Medical Center, Department of Surgery

Tochigi Cancer Center, Department of Surgery

Toho University Ohashi Medical Center, Department of Surgery III

Tokyo Medical University, Department of Surgery

Tokyo Women’s Medical University Medical Center East, Department of Surgery

Tokyo Women’s Medical University, Institute of Gastroenterology, Department of Gastroenterological Surgery

Wakayama Medical University, Department of Gastroenterological Surgery

Yamaguchi University Graduate School of Medicine, Department of Digestive Surgery and Surgical Oncology.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Naohiro Sata.

About this article

Cite this article

Sata, N., Kurashina, K., Nagai, H. et al. The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg 16, 485–492 (2009). https://doi.org/10.1007/s00534-009-0077-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00534-009-0077-7

Keywords

Navigation